Elequin Capital’s Ascendis Pharma A/S ASND Stock Holding History

Elequin Capital’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.07K	Sell	4 -17	-81%	-$3.97K	﹤0.01%	569
2026 Q1	$4.8K	Sell	21 -30	-59%	-$6.72K	﹤0.01%	387
2025 Q4	$10.9K	Buy	+51	New	+$10.5K	﹤0.01%	234
2025 Q1	–	Sell	-53	Closed	-$7.3K	–	344
2024 Q4	$7.3K	Buy	53 +47	+783%	+$6.18K	﹤0.01%	376
2024 Q3	$896	Buy	+6	New	+$810	﹤0.01%	335
2024 Q2	–	Sell	-50	Closed	-$7.56K	–	202
2024 Q1	$7.56K	Buy	+50	New	+$7.14K	﹤0.01%	126
2023 Q3	–	Sell	-44	Closed	-$3.93K	–	406
2023 Q2	$3.93K	Buy	+44	New	+$3.83K	﹤0.01%	394
2022 Q4	–	Sell	-76	Closed	-$8K	–	626
2022 Q3	$8K	Sell	76 -37	-33%	-$3.51K	﹤0.01%	285
2022 Q2	$11K	Buy	113 +94	+495%	+$8.86K	﹤0.01%	229
2022 Q1	$2K	Buy	+19	New	+$2.2K	﹤0.01%	252

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Elequin Capital's ASND Position: Q2 2026 in Review

Elequin Capital reduced its Ascendis Pharma A/S (ASND) stake by 81% in Q2 2026, selling an estimated $3.97K and leaving 4 shares worth $1.07K. The position accounts for ﹤0.01% of the portfolio, ranked #569.

Elequin Capital first reported a position in ASND in Q1 2022 and has held it in 10 quarters since. The position peaked at $11K in Q2 2022. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Elequin Capital held 4 shares of Ascendis Pharma A/S worth $1.07K as of Q2 2026.
Elequin Capital sold 17 Ascendis Pharma A/S shares in Q2 2026, an estimated $3.97K.
Ascendis Pharma A/S made up ﹤0.01% of Elequin Capital's portfolio in Q2 2026, its #569 holding.
Elequin Capital first reported a position in Ascendis Pharma A/S in Q1 2022 and has held it in 10 quarters since.
Elequin Capital's Ascendis Pharma A/S position peaked at $11K in Q2 2022.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Elequin Capital's 13F filing for Q2 2026, filed 13 Aug 2026.